Carebook Technologies (CRBK) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue increased 2% year-over-year to $3.6M, with 64% from the employer vertical and 36% from the pharmacy vertical, offsetting churn and maintaining margins despite unusual expenses.

• Net loss widened to $(0.7)M from $(0.4)M in Q3 2023, mainly due to higher expenses including a one-time bad debt expense and lower income tax recovery.

• Adjusted EBITDA was $0, down from $0.1M in Q3 2023; Adjusted EBITDA margin declined to (1)% from 3%.

• Annual recurring revenue (ARR) as of September 30, 2024, was $11.4M, a 2% decrease year-over-year, with 60% of ARR from clients outside Canada.

• Combined platforms served 5M users, with continued operational strengthening in pharmacy and employer verticals, product enhancements, and successful client implementations.

Financial highlights

• Q3 2024 revenue was $3.6M, up 2% year-over-year from $3.5M, driven by CoreHealth license revenue.

• Employer vertical contributed 64% of revenue; pharmacy vertical 36%.

• Net loss was $(0.7)M, compared to $(0.4)M in Q3 2023, due to higher expenses including a one-time bad debt expense.

• Adjusted EBITDA was $0, down from $0.1M (margin 3%) in Q3 2023; margin declined to (1)%.

• ARR at quarter-end was $11.4M, a 2% decrease year-over-year.

Outlook and guidance

• Recurring revenue from the employer vertical expected to increase as more clients enter the implementation pipeline.

• Management expects annual revenue growth and break-even Adjusted EBITDA for fiscal 2024, with a focus on cost control and cash flow improvement.

• Pharmacy revenue expected to decrease slightly in Q4 due to reduced scope of work.

• Plans to pursue accretive acquisitions and partnerships to expand offerings and market reach.

• Financial outlook based on assumptions regarding inflation, interest rates, customer adoption, and cost management.